Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $11.29M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Gilead Sciences USD 23.52B 18.55B Mar/2026
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Merck USD 18.17B 8.01B Mar/2026